Dorsa Jahangiri
1 
, Atousa Najmaldin
2* , Lakkakula VKS Bhaskar
3 1 Independent researcher, 43185 Cardston Place Leesburg Virginia, 20176, USA
2 Assistant Professor of Endocrinology & Metabolism, Department of Internal Medicine, School of Medicine, Semnan University of Medical Sciences
3 Professor of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India
Abstract
The sodium–glucose cotransporter-2 inhibitors (SGLT2i) are a new class of antidiabetic agents. SGLT2i are able to inhibit SGLT2 transporter in renal tissue, increasing glycosuria and reducing blood sugar. These drugs act by inhibiting the SGLT2 in renal proximal epithelial tubular cells. SGLT2i are found to have beneficial effect on chronic renal failure caused by diabetic nephropathy.
Implication for health policy/practice/research/medical education:
A study of SGLT2 inhibitors in type 1 and 2 diabetes individuals showed a reduction in hyperfiltration in normotensive, normoalbuminuric type 1 diabetes patients and a significant reduction in albuminuria and hyperfiltration in type 2 diabetes individuals.
Please cite this paper as: Jahangiri D, Najmaldin A, Bhaskar LVKS. Ameliorative impact of sodium–glucose cotransporter-2 inhibitors in diabetic kidney disease; a mini- review to current evidence. J Renal Inj Prev. 2022; 11(4): e31947. doi: 10.34172/ jrip.2022.31947.